Aristippos Gennadios - Catalent President - Softgel & Oral Technologies
CTLT Stock | USD 56.50 0.16 0.28% |
President
Dr. Aristippos Gennadios is President Softgel Technologies of the Company. Previously, Dr. Gennadios has served as our President, Softgel Technologies since September 2013. Previously, he served as Vice President and General Manager of Softgel Technologies. Dr. Gennadios has worked in the pharmaceutical industry since 1996 in roles including RD, field sales, business development, operations and leadership. He joined our predecessor company, Cardinal Health, in 2002 and has held several key leadership posts within the softgel technologies business, including Global Vice President of Business Development for Softgel Technologies, General Manager of the Oral Development Center in Somerset, NJ, and Vice President and General Manager for Prescription Softgel and Consumer Health products since 2020.
Age | 58 |
Tenure | 4 years |
Professional Marks | MBA |
Address | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 |
Phone | 732 537 6200 |
Web | https://www.catalent.com |
Catalent Management Efficiency
Return On Tangible Assets is likely to gain to -0.03 in 2024. Return On Capital Employed is likely to gain to -0.02 in 2024. At this time, Catalent's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 157.5 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 6.2 B in 2024. Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
William Barbo | Charles River Laboratories | 63 | |
Shawn Soderberg | Bio Rad Laboratories | 53 | |
Bernard Birkett | West Pharmaceutical Services | 55 | |
Cynthia Verst | IQVIA Holdings | N/A | |
Annette Favorite | West Pharmaceutical Services | 59 | |
Michael Knell | Charles River Laboratories | 47 | |
Jon Resnick | IQVIA Holdings | N/A | |
Nilton Paletta | IQVIA Holdings | N/A | |
Giovanni Magni | Bio Rad Laboratories | 63 | |
Warwick Bedwell | West Pharmaceutical Services | 55 | |
Karen Boylan | Teleflex Incorporated | 47 | |
Richard Staub | IQVIA Holdings | 54 | |
Ilan Daskal | Bio Rad Laboratories | 58 | |
Heino Lennartz | West Pharmaceutical Services | 49 | |
Ronald Hutton | Bio Rad Laboratories | 62 | |
Michael Anderson | West Pharmaceutical Services | 60 | |
Quintin Lai | West Pharmaceutical Services | 53 | |
Michael Crowley | Bio Rad Laboratories | 62 | |
Cameron Hicks | Teleflex Incorporated | 59 | |
James Erlinger | IQVIA Holdings | 57 | |
Timothy Ernst | Bio Rad Laboratories | 64 |
Management Performance
Return On Equity | -0.3 | ||||
Return On Asset | -0.0075 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthew Walsh, CFO and Executive VP | ||
Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
Paul Surdez, Vice Relations | ||
Bruce McEvoy, Director | ||
Aris Gennadios, President - Softgel Technologies | ||
Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
James Quella, Director | ||
Michael Hatzfeld, VP Officer | ||
Kay Schmidt, Senior Vice President - Technical Operations | ||
Karen Santiago, VP Office | ||
John Chiminski, Chairman of the Board, Chief Executive Officer | ||
Gregory Lucier, Independent Director | ||
Scott Houlton, President - Development and Clinical Services | ||
Rolf Classon, Independent Director | ||
Michael Barber, Independent Director | ||
Matti Masanovich, Senior CFO | ||
Martin Carroll, Director | ||
Julien Meissonnier, VP Officer | ||
Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
Alessandro Maselli, Senior Vice President - Global Operations | ||
Ricci Whitlow, President - Clinical Supply Services | ||
Charles Lickfold, Senior Vice President, Chief Information Officer | ||
Aristippos Gennadios, President - Softgel & Oral Technologies | ||
Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
Lance Miyamoto, Senior Vice President - Human Resources | ||
Rosemary Crane, Independent Director | ||
Sharon Johnson, Sr. VP of Quality, Product Devel., and Regulatory Affairs | ||
Joseph JD, General VP | ||
Peter Zippelius, Independent Director | ||
Jonathan Arnold, President - Oral & Specialty Delivery | ||
Ricky Hopson, Division President | ||
John MBA, Executive Board | ||
Donald Morel, Independent Director | ||
John Greisch, Independent Director | ||
Stephen Leonard, Sr. VP of Global Operations | ||
Chinh Chu, Chairman of the Board | ||
Steven Esq, Corp VP | ||
Karen Flynn, President - Biologics and Chief Commercial Officer | ||
Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
Christine Dolan, Senior Vice President - Product Development | ||
Christa Kreuzburg, Independent Director | ||
William Downie, Sr. VP of Global Marketing and Sales | ||
Lisa Evoli, Senior Officer | ||
Madhavan Balachandran, Independent Director | ||
J Carroll, Independent Director | ||
Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
Lucier Gregory, Director | ||
Barry Littlejohns, President - Advanced Delivery Technologies | ||
Melvin Booth, Director | ||
Jack Stahl, Lead Independent Director | ||
Uwe Rohrhoff, Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.3 | ||||
Return On Asset | -0.0075 | ||||
Profit Margin | (0.32) % | ||||
Operating Margin | (0.08) % | ||||
Current Valuation | 14.97 B | ||||
Shares Outstanding | 180.97 M | ||||
Shares Owned By Insiders | 0.50 % | ||||
Shares Owned By Institutions | 99.50 % | ||||
Number Of Shares Shorted | 7.19 M | ||||
Price To Earning | 17.80 X |
Pair Trading with Catalent
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalent position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalent will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Catalent could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalent when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalent - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalent to buy it.
The correlation of Catalent is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalent moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalent moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalent can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalent. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Catalent Stock please use our How to Invest in Catalent guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Catalent Stock analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Catalent's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalent. If investors know Catalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.15) | Earnings Share (7.18) | Revenue Per Share 22.579 | Quarterly Revenue Growth (0.11) | Return On Assets (0.01) |
The market value of Catalent is measured differently than its book value, which is the value of Catalent that is recorded on the company's balance sheet. Investors also form their own opinion of Catalent's value that differs from its market value or its book value, called intrinsic value, which is Catalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalent's market value can be influenced by many factors that don't directly affect Catalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.